BMI
Badger Meter, Inc.
BMI trails on the overall score without a compensating advantage in the available component scores.
NVDA
NVIDIA Corporation
NVDA has the edge over BMI overall, supported by stronger modeled upside and stronger fundamentals.
BMI Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Healthy | |
| Strong |
BMI's profitability, cash flow and balance sheet are currently healthy, and its revenue is stable.
NVDA Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Strong | |
| Strong | |
| Strong |
NVDA's revenue, profitability, cash flow and balance sheet are all currently strong.
BMI PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 32x | $154 | — |
| Current | 35x | $154 | — |
| Cheap | 37x | $160 | +4.3% |
| Fair | 49x | $212 | +38% |
| Expensive | 55x | $238 | +55% |
Historical ranges are pointers, not guarantees.
BMI's PE is in its cheap range at 35x. If earnings grow as analysts expect, today's price would be 32x next year's earnings.
NVDA PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $166 | — |
| Current | 21x | $166 | — |
| Cheap | 44x | $345 | +108% |
| Fair | 65x | $511 | +207% |
| Expensive | 93x | $734 | +342% |
Historical ranges are pointers, not guarantees.
NVDA has the edge over BMI in the historical PE scenario, which offers more potential upside but is not a forecast.
BMI Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Growth | |
| Stable | |
| Stable | |
| Limited | |
| Moderate |
Analysts expect BMI's earnings to grow, with its revenue and profitability holding steady.
NVDA Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Weakening | |
| Broad | |
| Moderate |
Analysts expect strong earnings and revenue growth for NVDA, but weaker profitability.
BMI Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $4.87 | +12% |
| Q3 2026 | $4.33 | -7.9% |
| Q2 2026 | $4.28 | -6.8% |
| Q1 2026 | $4.43 | -2.4% |
| Q4 2025 | $4.80 | +13% |
| Q3 2025 | $4.70 | +17% |
| Q2 2025 | $4.59 | +20% |
| Q1 2025 | $4.54 | +31% |
| Q4 2024 | $4.23 | +35% |
BMI earned $4.33 per share over the past year, down 7.9% from the year before.
NVDA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $13.77 | +74% |
| Q3 2026 | $7.91 | +125% |
| Q2 2026 | $6.53 | +111% |
| Q1 2026 | $4.90 | +67% |
| Q4 2025 | $4.03 | +59% |
| Q3 2025 | $3.51 | +65% |
| Q2 2025 | $3.10 | +81% |
| Q1 2025 | $2.94 | +147% |
| Q4 2024 | $2.54 | +234% |
NVDA has the edge over BMI on earnings, with more consistent year-over-year improvement.
BMI Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $235.9M | +0.1% |
| Q2 2026 | $222.3M | -6.6% |
| Q1 2026 | $202.3M | -9% |
| Q4 2025 | $220.7M | +7.6% |
| Q3 2025 | $235.7M | +13% |
| Q2 2025 | $238.1M | +9.9% |
| Q1 2025 | $222.2M | +13% |
| Q4 2024 | $205.2M | +12% |
BMI's revenue grew through 2024 and has held roughly level since: $236M last quarter, about level with the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 20% | +0.7 points |
| Q2 2026 | 18% | -1.1 points |
| Q1 2026 | 17% | -4.8 points |
| Q4 2025 | 20% | +0.4 points |
| Q3 2025 | 20% | +0.1 points |
| Q2 2025 | 19% | -0.3 points |
| Q1 2025 | 22% | +3.6 points |
| Q4 2024 | 19% | +1.5 points |
BMI's operating margin was 20% last quarter, up 0.7 points from the same quarter a year ago, near the top of its range since 2019.
NVDA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $96.2B | +106% |
| Q2 2026 | $81.6B | +85% |
| Q1 2026 | $68.1B | +73% |
| Q4 2025 | $57B | +62% |
| Q3 2025 | $46.7B | +56% |
| Q2 2025 | $44.1B | +69% |
| Q1 2025 | $39.3B | +78% |
| Q4 2024 | $35.1B | +94% |
NVDA has the edge over BMI on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 66% | +5.4 points |
| Q2 2026 | 66% | +17 points |
| Q1 2026 | 65% | +3.9 points |
| Q4 2025 | 63% | +0.8 points |
| Q3 2025 | 61% | -1.2 points |
| Q2 2025 | 49% | -16 points |
| Q1 2025 | 61% | -0.5 points |
| Q4 2024 | 62% | +4.9 points |
NVDA has the edge over BMI on profitability, with a higher operating margin.
BMI Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $40.3M | -16% |
| Q2 2026 | $21.9M | -46% |
| Q1 2026 | $29.5M | -2% |
| Q4 2025 | $50.8M | +7.1% |
| Q3 2025 | $48.2M | +15% |
| Q2 2025 | $40.6M | +19% |
| Q1 2025 | $30.1M | +60% |
| Q4 2024 | $47.4M | +32% |
BMI's free cash flow has been positive every quarter for seven years: $142M over the past year, down 14% from the year before.
NVDA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $21.4B | +59% |
| Q2 2026 | $48.6B | +86% |
| Q1 2026 | $34.9B | +124% |
| Q4 2025 | $22.1B | +32% |
| Q3 2025 | $13.5B | -0.3% |
| Q2 2025 | $26.2B | +75% |
| Q1 2025 | $15.6B | +38% |
| Q3 2024 | $13.5B | +113% |
NVDA has the edge over BMI on cash flow, with more consistent year-over-year improvement.
BMI Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.9% | -271K shares |
| 1 year | -2.4% | -712K shares |
| 3 years | -1.9% | -550K shares |
| 5 years | -1.3% | -395K shares |
BMI has the edge over NVDA on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $55.5M |
| Q2 2026 | $25.3M |
| Q1 2026 | $38.2M |
| Q4 2022 | — |
| Q3 2022 | — |
| Q4 2021 | — |
| Q3 2021 | — |
| Q4 2020 | $182,000 |
NVDA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -106M shares |
| 1 year | -1% | -247M shares |
| 3 years | -2.8% | -705M shares |
| 5 years | -4.1% | -1B shares |
| Available history | -1.8% | -435M shares |
NVDA has 24.3B diluted shares, down 1% from a year ago, with $55.3B in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q3 2026 | $19.7B |
| Q2 2026 | $19.3B |
| Q1 2026 | $3.8B |
| Q4 2025 | $12.5B |
| Q3 2025 | $9.7B |
| Q2 2025 | $14.1B |
| Q1 2025 | $7.8B |
| Q4 2024 | $11B |
NVDA spent $55.3B buying back its own shares over the past year, up 30% from the year before.
BMI Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.4x | Net Cash |
| Q2 2026 | -0.6x | Net Cash |
| Q1 2026 | -1.1x | Net Cash |
| Q4 2025 | -1.2x | Net Cash |
| Q3 2025 | -1.1x | Net Cash |
| Q2 2025 | -0.9x | Net Cash |
| Q1 2025 | -0.7x | Net Cash |
| Q4 2024 | -1.8x | Net Cash |
BMI has the edge over NVDA on leverage, with a lower net debt burden relative to earnings.
NVDA Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.1x | Very low |
| Q2 2026 | -0.0x | Net Cash |
| Q1 2026 | -0.0x | Net Cash |
| Q4 2025 | -0.0x | Net Cash |
| Q3 2025 | -0.0x | Net Cash |
| Q2 2025 | -0.1x | Net Cash |
| Q1 2025 | -0.0x | Very low |
| Q4 2024 | -0.0x | Net Cash |
NVDA's net debt is less than a year of its operating earnings (EBITDA), after holding more cash than debt a year ago.
BMI Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 57.6 | Neutral |
| Stochastic | 74.5 | Neutral |
BMI's weekly RSI is 58 (neutral) and its Stochastic is 75 (neutral).
NVDA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 33.4 | Neutral |
| Stochastic | 18.1 | Oversold |
NVDA's weekly RSI is 33 (neutral) and its Stochastic is 18 (oversold).
BMI PE vs Technology Sector
| Metric | BMI | Sector median | Relative |
|---|---|---|---|
| PE | 35x | 28x | 27% above |
| PE % | 14 | 35 | 21 pts below |
BMI is trading at 35x earnings, a 27% premium to the Technology sector's median of 28x.
NVDA PE vs Technology Sector
| Metric | NVDA | Sector median | Relative |
|---|---|---|---|
| PE | 21x | 28x | 25% below |
| PE % | 0 | 35 | 35 pts below |
NVDA has the edge over BMI on valuation relative to its sector.
BMI Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $140.8 | 9.1% above |
| 20 week MA | $137.7 | 12% above |
| 50 week MA | $144.3 | 6.4% above |
| 100 week MA | $174.9 | 12% below |
| 200 week MA | $169.6 | 9.5% below |
BMI has the edge over NVDA on trend strength, trading above more of its moving averages.
NVDA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $208.9 | 20% below |
| 20 week MA | $212.0 | 22% below |
| 50 week MA | $199.9 | 17% below |
| 100 week MA | $175.1 | 5.1% below |
| 200 week MA | $123.6 | 34% above |
NVDA has fallen below most of its moving averages, though it's still 34% above its 200-week average.
BMI Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $66.1 | $93.7 | +42% |
| 2021 | $93.7 | $105.2 | +12% |
| 2022 | $105.2 | $109.6 | +4.2% |
| 2023 | $109.6 | $154.4 | +41% |
| 2024 | $154.4 | $215.5 | +40% |
| 2025 | $215.5 | $180.8 | -16% |
| 2026 YTD | $180.8 | $153.6 | -15% |
BMI has finished higher in five of the last six years. It's down 15% so far in 2026.
NVDA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $5.92 | $13.0 | +119% |
| 2021 | $13.0 | $29.6 | +128% |
| 2022 | $29.6 | $15.2 | -49% |
| 2023 | $15.2 | $49.5 | +226% |
| 2024 | $49.5 | $137.0 | +177% |
| 2025 | $137.0 | $190.5 | +39% |
| 2026 YTD | $190.5 | $166.2 | -13% |
NVDA has the edge over BMI on returns for 2026, with the stronger performance.